araag2/HINT huggingface dataset:
Clinical trial NCT00003667 (phase 2, status: completed)
Conditions: sarcoma
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: cyclophosphamide, dexrazoxane hydrochloride, disaccharide tripeptide glycerol dipalmitoyl, doxorubicin hydrochloride, vincristine sulfate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, CC1=CC(O)=CC(C)=C1Cl, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically proven high risk Ewing's family of tumors: Ewing's
        sarcoma of bone Extraosseous Ewing's sarcoma Peripheral neuroepithelioma Must have one of
        the following characteristics: Metastatic disease at diagnosis Primary tumor of the
        humerus, femur, or trunk Bulky (greater than 8 cm) tumor Elevated LDH prior to biopsy (at
        least 900 IU/mL)

        PATIENT CHARACTERISTICS: Age: 3 to 60 Performance status: Not specified Life expectancy:
        Not specified Hematopoietic: Granulocyte count at least 500/mm3 Platelet count at least
        75,000/mm3 Hemoglobin at least 8 g/dL (transfusion allowed) Hepatic: Bilirubin no greater
        than 1.5 mg/dL SGOT or SGPT no greater than 3 times normal Renal: BUN less than 30 mg/dL
        Creatinine no greater than 1.5 times normal for age OR Creatinine clearance at least 70
        mL/min Cardiovascular: Ejection fraction at least 50% OR Fractional shortening at least 29%
        Other: Not pregnant or nursing Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not
        specified
Clinical trial NCT00830245 (phase 2, status: terminated)
Conditions: leptomeningeal carcinomatosis, non-small cell lung cancer
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    low accrual rate
  
Eligibility criteria:

        Inclusion Criteria:

          1. Age >18

          2. Histologically or pathologically proven non-small cell lung cancer (NSCLC)

          3. Leptomeningeal carcinomatosis confirmed by CSF cytology

          4. A patients with EGFR mutation (including exon 19 deletion, L858R)

          5. ECOG performance status 0-3

          6. Expected life time more than at least 4 weeks

          7. A patients who signed the informed consent prior to the participation in the study

          8. Chemotherapy-naïve patient is eligible

          9. Previous EGFR TKI is allowed if this drug was not specifically used for CNS metastases

        Exclusion Criteria:

          1. A pregnant or lactating patient

          2. A patient of childbearing potential without being tested for pregnancy at baseline or
             with a positive test. (A postmenopausal woman with the amenorrhea period of at least
             12 months or longer is considered to have non-childbearing potential.)

          3. A man or woman of childbearing potential without the willingness to use a
             contraceptive measures during the study

          4. A patient with history of another malignant disease within past 3 years, except
             curatively treated basal cell carcinoma of the skin, cervical carcinoma in situ, and
             early gastric cancer

          5. A patient with active interstitial lung disease, except simple lymphangitic lung
             metastasis

          6. A patient with history of allergic reaction to gefitinib or erlotinib

          7. The following laboratory test results:

               -  Number of absolute neutrophils counts (ANC) < 1.0ⅹ109/L

               -  Number of platelets < 50 ⅹ109/L

               -  AST, ALT > 2.5 ⅹupper limit of normal

               -  Total bilirubin > 1.5 ⅹupper limit of normal

               -  Serum creatinine > 1.5 ⅹupper limit of normal

          8. A patient with serious disease as followings

               -  Uncontrolled cardiac arrhythmia

               -  History of myocardial infarction within 6 months prior to the initiation of study

               -  Neurological or psychiatric disorder including dementia or uncontrolled seizure

          9. A patient who refused to sign the informed consent
Clinical trial NCT00206453 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: taxotere
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    accrual too difficult to meet
  
Eligibility criteria:

        Inclusion Criteria:

          1. All patients must be female

          2. Locally advanced breast cancers or primary breast cancers with concomitant gross
             metastatic disease are eligible; locally advanced cancers must be of clinical and/or
             radiologic size > 4 cm and/or are deemed surgically inoperable.

          3. Negative serum pregnancy test (beta-human chorionic gonadotropin [b-HCG]) within 7
             days of starting study, if of childbearing potential

          4. Kidney and liver function tests - all within 1.5 times of the institution's upper
             limit of normal

          5. Performance status (World Health Organization [WHO] scale) < 2 and life expectancy > 6
             months

          6. Age > 18 years old

          7. No brain and/or leptomeningeal disease

          8. No previous or current malignancies at other sites within the last 5 years, with the
             exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri
             and basal or squamous cell carcinoma of the skin.

        Exclusion Criteria:

          1. Pregnancy or unwillingness to use a reliable contraceptive method in women of
             child-bearing potential.

          2. Severe underlying chronic illness or disease

          3. Patients on other investigational drugs while on study will be excluded.
Clinical trial NCT00295672 (phase 2, status: completed)
Conditions: lung neoplasm
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: vinorelbine
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

        histologically or cytologically documented inoperable stage IIIA N2 or IIIB NSCLC
        previously untreated, absence of malignant pleural effusion, performance status (PS) =1 and
        patient life expectancy of at least 12 weeks.

        Exclusion Criteria:

        metastatic disease, small Cell lung carcinoma, prior chemotherapy, prior radiotherapy,
        resecable tumor, any instable systemic disease, any other malignancies within 5 years,
Clinical trial NCT01241214 (phase 2, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: act-129968, act-129968, cetirizine, placebo
SMILES: OC(=O)CN1C2=C(CN(CC2)C(=O)C2=CC=CC3=CC=CC=C23)C2=CC(F)=CC=C12, OC(=O)CN1C2=C(CN(CC2)C(=O)C2=CC=CC3=CC=CC=C23)C2=CC(F)=CC=C12, OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females aged 18 to 70 years.

          -  Clinical history of symptomatic seasonal allergic rhinitis associated with mountain
             cedar pollen for the last two years.

          -  Adequate exposure to mountain cedar pollen.

          -  Positive skin prick test to mountain cedar allergen within 12 months of screening.

          -  Sufficient nasal symptom score during a run-in period.

        Exclusion Criteria:

          -  Non-allergic rhinitis.

          -  Bacterial or viral respiratory tract infection.

          -  Chronic respiratory disorders.

          -  Asthma requiring treatment other than inhaled short-acting Beta2-agonists.

          -  Ocular infections or surgery, nasal obstruction, nasal biopsy or surgery, sinus
             surgery or perforation.

          -  Smoking within the last year.

          -  Ongoing or recent treatment for seasonal allergic rhinitis.

          -  Initiation of allergen immunotherapy within 6 months of screening.
Clinical trial NCT00321308 (phase 2, status: terminated)
Conditions: carcinoma, non-small cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: pemetrexed, pemetrexed + pf-3512676
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Locally advanced or metastatic NSCLC

          -  Measurable disease

          -  ECOG PS 0 or 1

        Exclusion Criteria:

          -  Known CNS metastasis

          -  Pre-existing autoimmune or antibody mediated disease
Clinical trial NCT00352105 (phase 1/phase 2, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: cisplatin, fluorouracil, iressa
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary* squamous cell carcinoma of the head and neck region,
             excluding any of the following:

               -  Nasopharynx

               -  Paranasal sinuses

               -  Salivary glands NOTE: *Primary site must be identified

          -  Locoregionally confined stage III or IV disease

               -  No evidence of nodal disease below the clavicles

               -  No distant hematogenous metastases (M0)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  WBC > 3,500/mm³

          -  Platelet count > 100,000/mm³

          -  Creatinine ≤ 2.0 mg/dL

          -  Alkaline phosphatase < 2 times normal

          -  AST < 2 times normal

          -  Bilirubin ≤ 2.0 mg/dL

          -  Calcium normal

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Must not be a poor compliance risk for follow-up

          -  No known severe hypersensitivity to gefitinib or any excipients of this drug

          -  No evidence of clinically active interstitial lung disease

               -  Patients with chronic, stable radiographic changes who are asymptomatic are
                  eligible

          -  No unstable or uncontrolled angina, clinically apparent jaundice, or active infection

          -  No history of any other malignancy (except squamous cell or basal cell skin cancer or
             cervical carcinoma in situ) unless disease free for ≥ 5 years

          -  No other severe, uncontrolled systemic disease (e.g., unstable or uncompensated
             respiratory, cardiac, hepatic, or renal disease)

        PRIOR CONCURRENT THERAPY:

          -  Recovered from prior oncologic or other major surgery

          -  No prior definitive surgery, radiotherapy, chemotherapy, immunotherapy, or epidermal
             growth factor receptor inhibitors for head and neck cancer

          -  No investigational drugs within the past 30 days

          -  No concurrent CYP3A4 inducers, including any of the following:

               -  Phenytoin

               -  Carbamazepine

               -  Rifampin

               -  Phenobarbital

               -  Hypericum perforatum (St. John's wort)

          -  Concurrent surgery allowed provided gefitinib is not administered 2 weeks before and 2
             weeks after surgery

          -  No concurrent aminoglycoside antibiotics
Clinical trial NCT00549822 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: letrozole
SMILES: N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Female

          -  18 years of age or older

          -  Postmenopausal

          -  Histologically or cytologically confirmed adenocarcinoma of the breast with locally
             advanced or metastatic disease this is not considered amenable to curative treatment
             with elevation of CA 15-3 documented at the time of diagnosis of metastatic disease
             and prior to initiation of letrozole or anastrozole therapy

          -  Current letrozole or anastrozole monotherapy with a documented CA 15-3 level that has
             decreased by at least 50% of the patients baseline

          -  Letrozole or anastrozole must be discontinued at the time of study enrollment

          -  Evidence of hormone sensitivity of primary or secondary tissue.

          -  Measurable or nonmeasurable (but evaluable-defined as nontarget lesions) disease
             according to modified RECIST

          -  Prior antiestrogen therapies including tamoxifen, steroidal AIs, nonsteroidal AIs, or
             fulvestrant in the adjuvant setting is allowed provided the patient is currently on
             letrozole or anastrozole monotherapy as first-line therapy for metastatic disease

          -  Life expectancy of greater than 3 months

          -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0,1, or 2

          -  Normal organ and marrow function as outlined in protocol

        Exclusion Criteria:

          -  Premenopausal

          -  Trastuzumab or biologic therapy within 2 weeks

          -  Prior or planned radiation therapy to a site of evaluable disease in the event that
             the site is the only site of evaluable disease

          -  Concomitant anticancer treatments including trastuzumab, chemotherapy, or other
             biologic agents other than letrozole or anastrozole therapy

          -  Chronic bisphosphonates for hypercalcemia or prevention of bone metastases.

          -  Treatment with non-approved or investigational agent within 2 weeks before study entry

          -  Presence of life-threatening metastatic disease, defined as extensive hepatic
             involvement, or past or present brain or leptomeningeal involvement, or symptomatic
             pulmonary lymphangitic spread

          -  Patients who are highly symptomatic from their breast cancer, or who require urgent
             palliative chemotherapy, as decided by their treating physician

          -  Previous or current systemic malignancy within the past five years, except for
             contralateral breast carcinoma, in situ carcinoma of the cervix treated by cone
             biopsy, or adequately treated basal or squamous cell carcinoma of the skin.

          -  Any severe concomitant condition believed to render subject undesirable for
             participation
Clinical trial NCT00176527 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: docetaxel, estramustine phosphate sodium, isotretinoin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H], C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
Reason stopped: 
    accrual goal met
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed hormone-refractory metastatic prostate cancer

               -  Patients who have been recently withdrawn from treatment with bicalutamide or
                  flutamide must demonstrate progression of disease

          -  Measurable disease OR prostate-specific antigen level ≥ 10 ng/mL

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Estimated life expectancy ≥ 6 months

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Hemoglobin ≥ 8 g/dL

          -  Platelet count ≥ 100,000/mm³

          -  Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min

          -  Bilirubin normal

          -  AST, ALT, and alkaline phosphatase (AP) must meet 1 of the following criteria:

               -  AP normal and AST and ALT ≤ 2.5 times upper limit of normal (ULN)

               -  AP elevated and AST and ALT normal

          -  No history of severe hypersensitivity reaction to docetaxel or other drugs formulated
             with polysorbate 80

          -  No peripheral neuropathy > grade 1

          -  No concurrent active infections

          -  No concurrent major depression or suicidal ideation

          -  No concurrent medical condition that would preclude study participation

          -  No known HIV positivity

          -  Fertile patients must use effective contraception during and for 10 weeks after
             completion of study therapy

        PRIOR CONCURRENT THERAPY:

          -  Recovered from prior surgery or radiotherapy

          -  No prior chemotherapy, retinoids, or interferon therapy

          -  More than 4 weeks since prior flutamide

          -  More than 6 weeks since prior bicalutamide
Clinical trial NCT01071083 (phase 2, status: completed)
Conditions: relapsing remitting multiple sclerosis
ICD codes: M94.1, A68.9, A68.0, A68.1, M35.6
Drugs: natalizumab, interferon beta 1-a, methylprednisolone, glatiramer acetate
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CC(O)=O
Eligibility criteria:

        Major criteria include:

          -  A diagnosis of a relapsing form of MS

          -  Treatment with natalizumab according to locally approved prescribing information

          -  Other protocol defined inclusion/exclusion criteria may apply
Clinical trial NCT01090622 (phase 1/phase 2, status: completed)
Conditions: primary erythromelalgia, inherited erythromelalgia
ICD codes: I73.81
Drugs: xpf-001, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        The study requires you to:

          -  Be18-75 years old

          -  Have inherited erythromelalgia

          -  Be experiencing pain caused by erythromelalgia (Moderate pain score 4/10)

          -  Be generally healthy (apart from your pain)

          -  Stop taking your usual pain medications for 9 days

          -  Not be pregnant or breast-feeding

        Your role in the study includes:

          -  An out-patient screening visit

          -  9-days/8 nights-in-patient treatment visit at Nijmegen Medical Center (where you will
             be closely monitored)

          -  A follow up phone call (after your return home)

          -  Taking the investigational medication daily

          -  Recording your pain levels daily during stay at the Medical Center.

        Exclusion Criteria:

          -  Coexistent source of pain from other conditions

          -  Receiving professional psychological support for dealing with IEM

          -  Treatment for significant depression within 6 months of screening

          -  Active HIV, Hepatitis B or C

          -  Use of prescription or OTC medication between check-in and discharge

          -  Women who are pregnant, or lactating

          -  Not currently using adequate contraception

          -  Alcoholism or alcohol or substance abuse

          -  Presence or history of major psychiatric disturbance

          -  Unwilling or unable to comply with all dietary and activity restrictions

          -  Any other condition or finding that may pose undue risk for participation

          -  Use of any other investigational drug in the 60 days prior to dosing
Clinical trial NCT00102206 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: abacavir sulfate, emtricitabine, lamivudine, lopinavir/ritonavir, saquinavir, tenofovir disoproxil fumarate, zidovudine
SMILES: NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, OC(=O)[C@@H]1CCCN1, [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria for Step I:

          -  HIV infected

          -  No currently available therapeutic options that would likely result in long-term
             suppression of virus to less than 400 copies/ml

          -  Two measurements within 4 months prior to screening and at screening of either CD4% of
             less than 15% and HIV viral load of greater than 10,000 copies/ml OR HIV viral load
             greater than 30,000 copies/ml

          -  Previous exposure to non-nucleoside reverse transcriptase inhibitors (NNRTIs), NRTIs,
             and PIs AND have experienced virologic failure. More information on previous treatment
             regimen requirements is available in the protocol.

          -  Prior or current virologic failure with genotypic or phenotypic resistance OR
             historical virologic failure with a PI- or NNRTI-containing regimen

          -  Resistance to 2 or more drugs in most recent treatment regimen within 26 weeks prior
             to study screening

          -  Able and willing to swallow study medications

          -  Parent or guardian willing to provide informed consent, if applicable

          -  Willing to use acceptable methods of contraception

        Exclusion Criteria for Step I:

          -  Previous cumulative exposure to TDF for more than 24 weeks OR more than 14 days of TDF
             exposure during the 24 weeks prior to study entry

          -  Grade 1 lipase or higher within 28 days prior to study entry

          -  Grade 3 or higher laboratory abnormality (except for lipase) within 28 days prior to
             study entry

          -  History of allergy or hypersensitivity to any of the study drugs

          -  Active CDC Stage C opportunistic infection or serious bacterial infection requiring
             therapy at the time of screening

          -  Chemotherapy for active cancer

          -  Require certain medications

          -  Abnormal kidney function

          -  Any clinically significant diseases other than HIV infection or findings during
             medical history screening that, in the opinion of the investigator, may interfere with
             the study

          -  Pregnancy or breastfeeding